{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Seattle&page=115&state=Washington",
    "query": {
      "state": "Washington",
      "city": "Seattle",
      "page": 115
    },
    "page_size": 10
  },
  "pagination": {
    "page": 115,
    "page_size": 10,
    "total_count": 11437,
    "total_pages": 1144,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Seattle&page=116&state=Washington&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Seattle&page=114&state=Washington&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T21:45:29.539Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04681638",
      "title": "Plasma Resuscitation Without Lung Injury",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Burns"
      ],
      "interventions": [
        {
          "name": "Pathogen-Reduced Plasma",
          "type": "DRUG"
        },
        {
          "name": "Crystalloid Solutions",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Coalition for National Trauma Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 13,
      "start_date": "2022-08-17",
      "completion_date": "2024-09-29",
      "has_results": false,
      "last_update_posted_date": "2025-01-29",
      "last_synced_at": "2026-11-21T21:45:29.539Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Nashville, Tennessee + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Fort Sam Houston",
          "state": "Texas"
        },
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04681638"
    },
    {
      "nct_id": "NCT03428958",
      "title": "A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Colorectal Neoplasms",
        "Colorectal Carcinoma",
        "Colorectal Tumors",
        "Neoplasms, Colorectal"
      ],
      "interventions": [
        {
          "name": "NUC-3373 + leucovorin",
          "type": "DRUG"
        },
        {
          "name": "NUC-3373",
          "type": "DRUG"
        },
        {
          "name": "NUFOX",
          "type": "DRUG"
        },
        {
          "name": "NUFOX + VEGF pathway inhibitor",
          "type": "DRUG"
        },
        {
          "name": "NUFOX + EGFR inhibitor",
          "type": "DRUG"
        },
        {
          "name": "NUFIRI",
          "type": "DRUG"
        },
        {
          "name": "NUFIRI + VEGF pathway inhibitor",
          "type": "DRUG"
        },
        {
          "name": "NUFIRI + EGFR inhibitor",
          "type": "DRUG"
        },
        {
          "name": "NUC-3373 + bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NuCana plc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2018-10-05",
      "completion_date": "2024-03-21",
      "has_results": true,
      "last_update_posted_date": "2025-04-23",
      "last_synced_at": "2026-11-21T21:45:29.539Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Durham, North Carolina • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03428958"
    },
    {
      "nct_id": "NCT03767348",
      "title": "Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer (NSCLC)",
        "Microsatellite Instability-High (MSI-H)",
        "Non-melanoma Skin Cancer (NMSC)",
        "Cutaneous Melanoma"
      ],
      "interventions": [
        {
          "name": "RP1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Replimune, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 340,
      "start_date": "2017-09-20",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-11-21T21:45:29.539Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03767348"
    },
    {
      "nct_id": "NCT00066248",
      "title": "Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Tumor",
        "Central Nervous System Tumors",
        "Cachexia",
        "Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "cyproheptadine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "megestrol acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "2 Years to 20 Years"
      },
      "enrollment_count": 70,
      "start_date": "2003-06",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2014-02-03",
      "last_synced_at": "2026-11-21T21:45:29.539Z",
      "location_count": 40,
      "location_summary": "Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00066248"
    },
    {
      "nct_id": "NCT04904055",
      "title": "Evaluating the Impact of a Value-based Prescription Drug Formulary",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Value-Based Health Insurance"
      ],
      "interventions": [
        {
          "name": "Value-based Formulary",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Kaiser Permanente",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "0 Years to 64 Years"
      },
      "enrollment_count": 36333,
      "start_date": "2015-01-01",
      "completion_date": "2019-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-05-27",
      "last_synced_at": "2026-11-21T21:45:29.539Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04904055"
    },
    {
      "nct_id": "NCT04590326",
      "title": "A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "REGN5668",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Ubamatamab",
          "type": "DRUG"
        },
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 612,
      "start_date": "2020-12-08",
      "completion_date": "2028-11-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-11-21T21:45:29.539Z",
      "location_count": 13,
      "location_summary": "Duarte, California • Irvine, California • Orange, California + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04590326"
    },
    {
      "nct_id": "NCT04951778",
      "title": "Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Myeloid, Acute",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "CC-91633",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2021-12-02",
      "completion_date": "2025-07-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-27",
      "last_synced_at": "2026-11-21T21:45:29.539Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • St Louis, Missouri • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04951778"
    },
    {
      "nct_id": "NCT01032044",
      "title": "CLE for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Barrett Syndrome",
        "Barrett's Syndrome",
        "Barrett's Esophagus",
        "Barrett Esophagus",
        "Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Standard endoscopic evaluation",
          "type": "DEVICE"
        },
        {
          "name": "pCLE guided evaluation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Mauna Kea Technologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2010-02",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2016-04-22",
      "last_synced_at": "2026-11-21T21:45:29.539Z",
      "location_count": 4,
      "location_summary": "Jacksonville, Florida • Chicago, Illinois • Kansas City, Missouri + 1 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01032044"
    },
    {
      "nct_id": "NCT00382109",
      "title": "Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "B-cell Childhood Acute Lymphoblastic Leukemia",
        "Childhood Acute Lymphoblastic Leukemia in Remission",
        "Graft Versus Host Disease",
        "L1 Childhood Acute Lymphoblastic Leukemia",
        "L2 Childhood Acute Lymphoblastic Leukemia",
        "T-cell Childhood Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "sirolimus",
          "type": "DRUG"
        },
        {
          "name": "total body irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 146,
      "start_date": "2007-03",
      "completion_date": "2017-06-30",
      "has_results": true,
      "last_update_posted_date": "2019-08-07",
      "last_synced_at": "2026-11-21T21:45:29.539Z",
      "location_count": 44,
      "location_summary": "Phoenix, Arizona • Duarte, California • Oakland, California + 40 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00382109"
    },
    {
      "nct_id": "NCT04928209",
      "title": "Teletherapy in Children Who Are Deaf and Hard of Hearing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hearing Loss",
        "Speech and Language Development Delay Due to Hearing Loss"
      ],
      "interventions": [
        {
          "name": "Speech-Language Teletherapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Months",
        "maximum_age": "27 Months",
        "sex": "ALL",
        "summary": "0 Months to 27 Months"
      },
      "enrollment_count": 210,
      "start_date": "2021-07-15",
      "completion_date": "2025-12-17",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-11-21T21:45:29.539Z",
      "location_count": 5,
      "location_summary": "Oakland, California • Palo Alto, California • San Diego, California + 2 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04928209"
    }
  ]
}